Vascular signaling
Conceptual educational illustration of Vesugen in a glass vial, labelled MOLECULE PROFILE.

View full illustrationSave Vesugen

MOLECULE PROFILE

Vesugen

Peptide or peptide-related

Vascular/cellular aging hypotheses.

Sources checked · October 16, 2026

Published for review · Scientific, medical, translation and citation review pending. Reported uses are not authorized indications. Frequency reflects mentions in supplied sources, not sales or global clinical prevalence.

Identity and synonyms

Identity follows the supplied name and synonyms; no additional identity description is supplied.

Peptide or peptide-related · Peptide or peptide derivative

Detailed molecular class: Bioregulator peptide

Supplied sequence or chemical reference

See identity note; no supplier sequence accepted as verification.

Mechanism

Vascular/cellular aging hypotheses.

Evidence and critical reading

Reported scientific and empirical uses

Aging research · Cardiovascular and vascular function

Promoted for vascular aging/cognitive function.

Human evidence

Small geriatric report with unclear controls and internally inconsistent participant totals; cannot establish rejuvenation or genetic safety.

Preclinical evidence

Cell-based endpoints cannot demonstrate lifespan extension.

Critical reading and limitations

The small geriatric report has unclear controls/inconsistent counts; it does not prove life extension.

Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.

Source-specific regimens

Descriptive source observations, not individual recommendations.

Regulatory product labeling

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Human-study exposure

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Empirical handbook

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Regulation and safety

Jurisdiction-specific regulatory context

Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.

Adverse effects and unknowns

Human safety, contraindications and interactions are not adequately established for the catalog product. Missing reports are not evidence of safety.

Genetic/hematological safety cannot be concluded from isolated biomarkers.

Contraindications

See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.

A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.

Interactions

Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.

Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.

Studies and trials

Selected studies

No selected studies are attributed in this record.

Trials attributed in the package

No trials are attributed in this record.

Trial registration does not establish efficacy or validate commercial material.

Query candidates; attribution pending

Vesugen · 0 unfiltered query results, not authenticated trials

Query verification: October 16, 2026

Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.

View trial registry query

Source issues and references

References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

  1. PMID26390612

    [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].

    Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE.

    October 16, 2026

  2. pdf01

    PEPNEXA 2.pdf

    October 16, 2026

  3. pdf05

    PEPNEXA.pdf

    October 16, 2026

  4. pdf09

    PeptideFactory.pdf

    October 16, 2026

A community-based bilingual scientific education initiative for healthcare professionals and the general public across the Americas.Currently self-funded; no current sponsors. Formal governance and legal documentation pending.info@peptideamericas.org · Planned contact address — not active yet; please do not send messages.